Baidu
map

BMC Cancer:乳腺癌患者体重指数(BMI)与生存呈U型关系

2015-12-23 MedSci译 MedSci原创

诊断乳腺癌时BMI和患者预后的联系依旧存在争议,不同乳腺癌亚型之间BMI和预后间关系更是不清不楚。研究者对KBCR数据库里1988年1月-2008年2月的41,021名浸润性乳腺癌进行了数据分析。使用Kaplan-Meier方法和Cox比例风险模型对所有患者和不同乳腺癌亚组患者进行分析,评估BMI和整体生存(OS)、乳腺癌特异性生存 (BCSS)间联系。研究数据显示,就整个队列而言BMI与死亡率间

诊断乳腺癌时BMI和患者预后的联系依旧存在争议,不同乳腺癌亚型之间BMI和预后间关系更是不清不楚。

研究者对KBCR数据库里1988年1月-2008年2月的41,021名浸润性乳腺癌进行了数据分析。使用Kaplan-Meier方法和Cox比例风险模型对所有患者和不同乳腺癌亚组患者进行分析,评估BMI和整体生存(OS)、乳腺癌特异性生存 (BCSS)间联系。

研究数据显示,就整个队列而言BMI与死亡率间呈U形联系,体重不足和肥胖均会比正常体重范围内患者有更糟糕的OS (HR, 1.23 [95 % CI, 1.05 to 1.44] ; 1.29 [1.13 to 1.48]) 和BCSS(1.26 [1.03 to 1.54];1.21 [1.02 to 1.43]) 。ER+/PR+/HER2-亚组患者,与正常体重患者相比,肥胖会导致更糟糕的OS(1.48 [1.18 to 1.85])和BCSS(1.31 [1.13 to 1.52])。在ER-/PR-/HER2+亚组中,与正常体重患者相比,体重不足会导致更糟糕的OS (1.68 [1.12 to 2.47])和BCSS (1.79 [1.11 to 2.90]) 。

研究结果表明,诊断乳腺癌时的BMI与整体乳腺癌患者预后(OS和BCSS)呈现U形联系。ER+/PR+/HER2-亚组患者中肥胖以及ER-/PR-/HER2+亚组患者中的体重不足会导致不良预后。因此对乳腺癌患者的治疗决策和监测计划中应加入BMI。

原始出处:

Jeon YW, Kang SH,BMC Cancer. et al.Relationship between body mass index and the expression of hormone receptors or human epidermal growth factor receptor 2 with respect to breast cancer survival.BMC Cancer. 2015 Nov 6;15:865.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1974658, encodeId=eee519e465825, content=<a href='/topic/show?id=f145355379' target=_blank style='color:#2F92EE;'>#BMC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3553, encryptionId=f145355379, topicName=BMC)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Fri Jan 01 03:58:00 CST 2016, time=2016-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=49209, encodeId=dc7f492094a, content=哟不错哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=142, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=58d871132, createdName=ran2233, createdTime=Sun Dec 27 10:54:00 CST 2015, time=2015-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1570977, encodeId=93f815e0977e3, content=<a href='/topic/show?id=f42823e48d7' target=_blank style='color:#2F92EE;'>#乳腺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23748, encryptionId=f42823e48d7, topicName=乳腺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37bc15724202, createdName=hanhaisha2013, createdTime=Fri Dec 25 03:58:00 CST 2015, time=2015-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=47316, encodeId=55614e316b7, content=应该是这样子, beContent=null, objectType=article, channel=null, level=null, likeNumber=162, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Wed Dec 23 22:13:00 CST 2015, time=2015-12-23, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1974658, encodeId=eee519e465825, content=<a href='/topic/show?id=f145355379' target=_blank style='color:#2F92EE;'>#BMC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3553, encryptionId=f145355379, topicName=BMC)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Fri Jan 01 03:58:00 CST 2016, time=2016-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=49209, encodeId=dc7f492094a, content=哟不错哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=142, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=58d871132, createdName=ran2233, createdTime=Sun Dec 27 10:54:00 CST 2015, time=2015-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1570977, encodeId=93f815e0977e3, content=<a href='/topic/show?id=f42823e48d7' target=_blank style='color:#2F92EE;'>#乳腺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23748, encryptionId=f42823e48d7, topicName=乳腺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37bc15724202, createdName=hanhaisha2013, createdTime=Fri Dec 25 03:58:00 CST 2015, time=2015-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=47316, encodeId=55614e316b7, content=应该是这样子, beContent=null, objectType=article, channel=null, level=null, likeNumber=162, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Wed Dec 23 22:13:00 CST 2015, time=2015-12-23, status=1, ipAttribution=)]
    2015-12-27 ran2233

    哟不错哦

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1974658, encodeId=eee519e465825, content=<a href='/topic/show?id=f145355379' target=_blank style='color:#2F92EE;'>#BMC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3553, encryptionId=f145355379, topicName=BMC)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Fri Jan 01 03:58:00 CST 2016, time=2016-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=49209, encodeId=dc7f492094a, content=哟不错哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=142, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=58d871132, createdName=ran2233, createdTime=Sun Dec 27 10:54:00 CST 2015, time=2015-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1570977, encodeId=93f815e0977e3, content=<a href='/topic/show?id=f42823e48d7' target=_blank style='color:#2F92EE;'>#乳腺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23748, encryptionId=f42823e48d7, topicName=乳腺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37bc15724202, createdName=hanhaisha2013, createdTime=Fri Dec 25 03:58:00 CST 2015, time=2015-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=47316, encodeId=55614e316b7, content=应该是这样子, beContent=null, objectType=article, channel=null, level=null, likeNumber=162, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Wed Dec 23 22:13:00 CST 2015, time=2015-12-23, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1974658, encodeId=eee519e465825, content=<a href='/topic/show?id=f145355379' target=_blank style='color:#2F92EE;'>#BMC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3553, encryptionId=f145355379, topicName=BMC)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Fri Jan 01 03:58:00 CST 2016, time=2016-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=49209, encodeId=dc7f492094a, content=哟不错哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=142, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=58d871132, createdName=ran2233, createdTime=Sun Dec 27 10:54:00 CST 2015, time=2015-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1570977, encodeId=93f815e0977e3, content=<a href='/topic/show?id=f42823e48d7' target=_blank style='color:#2F92EE;'>#乳腺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23748, encryptionId=f42823e48d7, topicName=乳腺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37bc15724202, createdName=hanhaisha2013, createdTime=Fri Dec 25 03:58:00 CST 2015, time=2015-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=47316, encodeId=55614e316b7, content=应该是这样子, beContent=null, objectType=article, channel=null, level=null, likeNumber=162, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Wed Dec 23 22:13:00 CST 2015, time=2015-12-23, status=1, ipAttribution=)]
    2015-12-23 lovetcm

    应该是这样子

    0

相关资讯

Sci Transl Med:CK1δ有望成为乳腺癌治疗的新靶点

酪蛋白激酶1δ(CaseinKinase 1δ,CK1δ)是酪蛋白激酶 I (Casein Kinase 1,CK1)的一个亚型,CK1是一类具有独特理化特性的丝氨酸/苏氨酸蛋白激酶,广泛存在于真核生物中,主要分布在细胞质、细胞核、细胞膜及细胞骨架等部位,参与多种细胞功能及发育过程的调节,具有重要功能。Wnt通路对于动物发育是必需的,参与干细胞分化及肿瘤的形成过程,而在Wnt通路中,CK1δ作为β

BMC Cancer:基因多态性影响乳腺癌化疗后生存

未来基于临床和基因特征的个体化治疗将会大大改善乳腺癌患者的生存和预后。现今广泛使用的化疗和放疗会引起DNA氧化损伤,若不能及时修复,进而出现细胞死亡。研究者假设与DNA氧化损伤相关的碱基切除修复(BER)通路的生殖系遗传变异将会影响乳腺癌患者生存。研究者纳入了German MARIE研究的1,408名绝经后乳腺癌患者,探究21个BER基因的127种单核苷酸多态性 (SNPs)对患者辅助化疗、蒽环霉

BMC Cancer:“神药”阿司匹林还可以预防乳腺癌?

乳腺癌变模型实验中发现非甾体类抗炎药 (NSAIDs) 会抑制其中致癌的几种途径,但是能否使用NSAIDs作为乳腺癌预防药物?目前仍缺乏相关流行病学数据。研究者进行了前瞻性队列研究,探究NSAIDs与乳腺癌风险间联系。该研究纳入了姊妹里有乳腺癌患者的女性,总共有 50,884人,随访期间共发生了2118例乳腺癌。使用“片-年”估计一生中NSAID的使用情况,1片-年意味着一年时间里每周吃1片。校正

BMC Cancer:血清鸢尾素(irisin )或可用于乳腺癌的诊断

鸢尾素是近期发现的与白色脂肪组织褐变相关的肌细胞因子,数据显示该物质的功能主要与能量平衡和代谢有关,同时可以作为潜在的肥胖或代谢性疾病治疗目标。研究者进行了一项研究,探究鸢尾素与乳腺癌的关系。研究者纳入了101名导管浸润性乳腺癌患者和51名健康女性,定量检测了其血清鸢尾素、瘦素、脂联素、抵抗素含量,以及血清 CEA、CA 15-3 、Her-2/neu情况。通过逻辑回归探究鸢尾素与乳腺癌的关系。使

BMC Cancer:饮酒和乳腺癌

研究者进行了一项研究,探究酒精摄入与乳腺癌风险间关系,同时调查超重和肥胖对该联系的影响。研究纳入了1991-1992年的45,233名女性,随访截止时间2009年12月。使用泊松回归模型分别对整体乳腺癌、ER+或ER-乳腺癌、PR+或PR-乳腺癌进行分析。随访期间共发生了1385例乳腺癌。研究数据显示,校正混杂因素后,未发生饮酒与乳腺癌风险间联系,每天摄入5g酒精时乳腺癌风险RR=1.01 (95

JAMA: 乳腺癌患者化疗过程中,服用曲普瑞林有利于卵巢功能恢复

化疗期间促黄体激素释放激素类似物(LHRHa)的管理是否是保护卵巢功能的一个可靠的战略,还是存在争议的,这是由于缺乏长期卵巢功能和妊娠的数据,以及对于在内分泌疗法和化学疗法之间考虑到潜在的负面相互作用的安全问题。原始出处:Matteo Lambertini,Luca Boni,Andrea Michelotti,et al.Ovarian Suppression With Triptorelin

Baidu
map
Baidu
map
Baidu
map